This is a non-core endpoint: only basic statistics are computed.
See these related core endpoints for full statistics:
Use of entacapone
PDMED_ENTACAPONE
No definition available.
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
520210 |
1. Apply sex-specific ruleNone |
520210 |
2. Check conditionsNone |
520210 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
1 out of 7 registries used, show all original rules. |
306 |
4. Check minimum number of events
Min. number of events
3
|
306 |
5. Include endpointsNone |
306 |
6. Filter based on genotype QC (FinnGen only) |
306 |
Control definitions (FinnGen only)
Controls for this endpoint are individuals that are not cases.
Extra metadata
- First used in FinnGen datafreeze
- DF2
Similar endpoints
↥List of similar endpoints to
Use of entacapone
based on the number of shared cases.
Similar with more cases:
- Use of levodopa decarboxylase inhibitor
- Parkinson's disease
- Parkinson's disease, excluding more controls
- Parkinson's disease, including avohilmo
- Extrapyramidal and movement disorders
Similar with less cases:
None
Case counts by codes
↥Summary Statistics
↥-FinRegistry-
This endpoint is excluded from FinRegistry analyses (omitted endpoint).
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 306 | 112 | 194 |
| Unadjusted period prevalence (%) | 0.07 | 0.04 | 0.09 |
| Median age at first event (years) | 69.00 | 67.08 | 70.11 |
-FinnGen-
Age distribution of first events
-FinnGen-
Year distribution of first events
-FinnGen-
Cumulative Incidence Function
Not a core endpoint, no data to show.
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 271
- Matched controls
- 2707
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
N04BX02
ATC
entacapone; oral
+∞
323.0
271
*
G20
ICD-10 Finland
Parkinson disease
4275.2
323.0
268
49
110
Kela drug reimbursment
Parkinson's disease and comparable movement disrorders
6756.1
323.0
269
49
N04BA02
ATC
levodopa and decarboxylase inhibitor; oral
+∞
323.0
271
61
N04BD01
ATC
selegiline; oral
374.5
219.1
197
19
N04BA03
ATC
levodopa, decarboxylase inhibitor and COMT inhibitor; oral
585.0
212.7
186
10
N04BC05
ATC
pramipexole; oral
47.7
141.3
182
111
N04BC04
ATC
ropinirole; oral
113.3
91.6
96
13
N04BD02
ATC
rasagiline; oral
219.4
90.4
89
6
N87
ICPC
Parkinsonism
73.5
83.4
93
19
193
Kela drug reimbursment
Rasagiline
188.0
80.0
80
6
F02.39*G20
ICD-10 Finland
Dementia in Parkinson's disease without information on additional symptoms
217.7
78.8
78
5
N04BB01
ATC
amantadine; oral
61.3
59.9
69
15
N04BC02
ATC
pergolide; oral
+∞
54.0
50
*
N05AH04
ATC
quetiapine; oral
9.6
50.6
120
207
G02CB01
ATC
bromocriptine; systemic
156.3
49.7
51
*
AAG20
NOMESCO Finland
Stereotactic intracranial implantation of electrodes
449.2
40.2
39
*
N04BC06
ATC
cabergoline; oral (dopamine agonists)
+∞
38.5
36
*
N04BC09
ATC
rotigotine; transdermal
142.2
35.7
37
*
N06DA03
ATC
rivastigmine; oral, transdermal
11.7
35.0
68
75
AEA50
NOMESCO Finland
Adjustment of implanted neurostimulator
378.2
33.7
33
*
N03AE01
ATC
clonazepam; systemic
12.6
33.4
62
62
N04AA02
ATC
biperiden; systemic
24.7
31.2
44
21
AEA00
NOMESCO Finland
Replacement of impulse generator of stimulation device in the nervous system
95.6
24.1
26
*
3320A
ICD-9 Finland
Parkinson's disease, Paralysis agitans
91.5
23.1
25
*
A06AD11
ATC
lactulose; oral
3.6
18.1
99
370
307
Kela drug reimbursment
Tacrine, donepezil, rivastigmine, galantamine and other major and expensive drugs used to treat Alzheimer's disease
5.2
17.6
58
134
H02AA02
ATC
fludrocortisone; oral
23.8
17.2
24
11
N04BC01
ATC
bromocriptine; oral
+∞
16.8
16
*
N04BX01
ATC
tolcapone; oral
+∞
16.8
16
*
F02.39
ICD-10 Finland
Dementia in Parkinson's disease without information on additional symptoms
180.7
16.7
17
*
XA800
NOMESCO Finland
Neuropsychological investigation
10.0
16.5
33
37
G21.9
ICD-10 Finland
Secondary parkinsonism, unspecified
50.8
16.2
19
*
WYA30
NOMESCO Finland
Preparations for expected poor cooperation
5.5
15.0
46
97
JDB10
NOMESCO Finland
Percutaneous gastrostomy
17.0
14.2
22
14
ZXM20
NOMESCO Finland
Intraoperative use of computerised tomography
42.4
13.3
16
*
R25.1
ICD-10 Finland
Tremor, unspecified
7.8
11.9
27
38
N39.0
ICD-10 Finland
Urinary tract infection, site not specified
3.2
11.6
67
249
N05BA04
ATC
oxazepam; oral
2.7
11.1
90
419
R13
ICD-10 Finland
Dysphagia
4.9
10.9
36
82
W01
ICD-10 Finland
Fall on same level from slipping, tripping and stumbling
2.5
10.8
118
647
R47.1
ICD-10 Finland
Dysarthria and anarthria
16.9
10.5
16
10
N05AH02
ATC
clozapine; systemic
41.7
10.0
12
*
G25.9
ICD-10 Finland
Extrapyramidal and movement disorder, unspecified
14.1
9.8
16
12
I95.1
ICD-10 Finland
Orthostatic hypotension
4.8
9.2
30
68
N10
ICD-10 Finland
Acute tubulo-interstitial nephritis
2.8
8.4
60
253
N06AB10
ATC
escitalopram; oral
2.9
8.3
54
215
N06AB04
ATC
citalopram; systemic
2.4
7.7
75
373
AA1AA
NOMESCO Finland
Head X-ray examination
25.8
7.6
10
*
N06AX11
ATC
mirtazapine; oral
2.2
7.6
91
502
R53
ICD-10 Finland
Malaise and fatigue
2.3
7.6
78
400
JX1LA
NOMESCO Finland
Kinetic X-ray of alimentary tract with pictures
82.3
7.5
8
*
XKD06
NOMESCO Finland
Physiologic investigation of micturition
5.5
7.4
21
41
N86
ICPC
Multiple sclerosis
+∞
7.3
7
*
S01.0
ICD-10 Finland
Open wound of scalp
3.2
7.2
38
132
S72.0
ICD-10 Finland
Fracture of neck of femur
3.7
7.2
31
92
G04BD12
ATC
mirabegron; oral
2.9
7.2
44
167
N06AX03
ATC
mianserin; oral
4.4
7.0
24
58
C07AA05
ATC
propranolol; systemic
2.6
6.8
51
220
R4130
NOMESCO Finland
Speech therapy
6.7
6.7
16
25
N05CD07
ATC
temazepam; oral
2.3
6.6
63
310
A98
ICPC
Health maint/preventive medicine
0.5
6.6
140
1831
ZXM10
NOMESCO Finland
Intraoperative use of conventional X-ray imaging
4.1
6.6
24
62
R1250
NOMESCO Finland
Evaluation of functional capability
7.7
6.5
14
19
N04AA01
ATC
trihexyphenidyl; oral
71.5
6.5
7
*
N19
ICPC
Speech disorder
14.8
6.4
10
7
N30.0
ICD-10 Finland
Acute cystitis
2.6
6.3
47
203
N04BC07
ATC
apomorphine; parenteral
+∞
6.3
6
*
AAW01
NOMESCO Finland
Implantation of intracranial stimulation device
+∞
6.3
6
*
N02AE01
ATC
buprenorphine; parenteral, sublingual, transdermal
2.4
6.3
56
267
N30.9
ICD-10 Finland
Cystitis, unspecified
3.6
6.1
26
77
I10
ICD-10 Finland
Essential (primary) hypertension
0.5
6.1
102
1448
R29.8
ICD-10 Finland
Other and unspecified symptoms and signs involving the nervous and musculoskeletal systems
3.2
6.1
31
106
K59.09
ICD-10 Finland
Constipation, unspecified
3.5
6.0
27
84
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
111
1829
0.38
14.45
3.2
4.3
1.2
1.3
mmol/l
0.08
97
1610
118
1883
0.39
14.01
3.3
4.8
1.4
1.4
mmol/l
1.10
102
1669
120
1896
0.40
13.80
3.3
4.9
4.2
4.4
mmol/l
1.51
106
1702
134
1957
0.44
11.20
3.4
5.5
2.4
2.5
mmol/l
0.80
114
1729
130
1906
0.45
10.67
5.2
6.7
40.0
41.5
mmol/mol
1.00
120
1724
140
1946
0.48
8.89
3.6
5.1
5.8
6.2
mmol/l
2.64
122
1709
160
2102
0.50
8.09
7.4
11.0
14.2
23.5
u/l
15.59
139
1994
73
1177
0.50
6.20
2.3
3.1
58.6
54.5
u/l
0.08
67
1069
144
1873
0.56
5.70
20.5
16.9
86.2
71.5
ml/min/173m2
15.17
116
1540
139
1812
0.57
5.37
4.1
4.6
1.9
2.0
mu/l
0.59
127
1574
113
1534
0.58
4.86
2.9
4.2
12.6
15.2
mm/h
1.18
106
1374
61
953
0.55
4.22
4.7
5.3
5.7
3.9
ug/l
0.30
55
825
17
61
2.89
3.75
3.2
4.5
26.8
33.4
mg/l
0.39
12
41
170
2022
0.64
3.53
21.4
17.7
30.3
26.7
mg/l
0.61
148
1673
132
1653
0.65
3.46
4.6
7.4
84.3
80.3
u/l
0.41
119
1533
32
574
0.51
3.37
3.3
2.8
16706.1
9831.0
umol/l
0.25
26
464
58
867
0.59
3.23
3.0
3.2
1676.9
2009.0
ng/l
0.22
49
735
115
1452
0.67
2.92
3.3
3.8
14.5
15.1
pmol/l
1.57
100
1252
89
1180
0.65
2.86
3.7
6.0
9.9
11.9
umol/l
1.98
83
1108
6
11
5.54
2.55
1.3
1.8
—
—
—
0
0
60
841
0.64
2.43
2.8
2.7
150.7
149.7
ug/l
0.01
52
748
56
383
1.57
2.26
3.6
2.9
1.0
1.0
e6/l
0.05
29
221
144
1694
0.72
2.19
23.6
19.0
37.3
38.3
%
0.43
90
1033
54
370
1.56
2.16
3.7
3.1
2.4
1.5
e6/l
0.36
27
213
93
1175
0.70
2.15
8.8
8.7
4.6
4.3
e9/l
0.41
71
1018
14
273
0.49
1.89
2.9
4.4
2.9
52.4
ug/l
—
8
238
56
761
0.68
1.89
4.4
4.6
14.1
21.8
%
4.81
22
399
78
997
0.71
1.87
4.5
4.5
37.3
47.1
ng/l
0.27
61
776
37
541
0.64
1.78
2.8
3.1
0.6
0.9
ug/l
1.92
26
377
42
288
1.53
1.69
2.1
1.7
—
—
—
0
0
103
834
1.35
1.69
4.0
3.4
—
—
—
0
0
13
248
0.50
1.66
1.8
2.6
3.3
7.0
ug/l
2.18
13
214
9
184
0.47
1.56
2.3
3.3
4.9
5.2
kpa
—
9
167
0
43
0.00
1.53
0.0
1.1
—
30.1
—
0
37
82
653
1.35
1.48
4.4
3.3
0.3
0.5
e6/l
1.21
63
501
9
180
0.48
1.44
1.1
1.3
—
—
—
0
0
41
290
1.48
1.44
2.2
1.8
—
—
—
0
0
50
652
0.72
1.31
2.8
2.1
3.4
3.3
mg/l
0.05
40
540
41
543
0.72
1.18
2.0
1.9
347.3
13164410.6
pmol/l
0.50
34
433
0
34
0.00
1.16
0.0
1.1
—
—
—
0
0
89
1037
0.80
0.99
4.6
4.1
34.6
34.5
g/l
0.02
84
950
0
29
0.00
0.98
0.0
1.1
—
—
—
0
0
0
29
0.00
0.98
0.0
4.5
—
—
—
0
0
0
29
0.00
0.98
0.0
1.6
—
—
—
0
0
0
30
0.00
0.98
0.0
1.6
—
—
—
0
0
0
30
0.00
0.98
0.0
1.6
—
—
—
0
0
0
30
0.00
0.98
0.0
1.6
—
—
—
0
0
0
30
0.00
0.98
0.0
1.6
—
—
—
0
0
34
449
0.73
0.97
1.5
1.7
1.2
1.5
mg/l
0.26
28
361
0
31
0.00
0.97
0.0
1.5
—
—
—
0
0
0
31
0.00
0.97
0.0
1.4
—
—
—
0
0
36
273
1.36
0.91
5.4
3.9
—
—
—
0
0
72
604
1.25
0.88
1.9
1.7
21.0
20.7
nmol/l
0.05
62
493
104
1170
0.83
0.79
5.2
6.1
1.2
1.2
mmol/l
0.14
94
954
0
25
0.00
0.79
0.0
2.9
—
—
—
0
0
0
27
0.00
0.78
0.0
1.2
—
—
—
0
0
0
28
0.00
0.76
0.0
1.4
—
253.7
—
0
28
67
784
0.81
0.76
3.3
3.0
2.3
2.3
mmol/l
0.95
61
672
69
587
1.23
0.75
5.0
4.5
0.0
0.0
estimate
0.00
24
196
122
1344
0.85
0.72
5.1
4.7
6.3
6.9
mmol/l
3.86
117
1266
0
20
0.00
0.60
0.0
1.1
—
—
—
0
0
0
20
0.00
0.60
0.0
1.1
—
—
—
0
0
0
21
0.00
0.60
0.0
1.9
—
—
—
0
0
0
22
0.00
0.59
0.0
1.8
—
—
—
0
0
0
22
0.00
0.59
0.0
1.8
—
—
—
0
0
0
22
0.00
0.59
0.0
1.8
—
—
—
0
0
0
23
0.00
0.58
0.0
1.8
—
—
—
0
0
112
1018
1.16
0.58
5.1
4.2
0.0
0.0
estimate
0.00
23
208
20
150
1.36
0.57
2.0
1.7
—
—
—
0
0
111
1020
1.14
0.48
7.7
5.7
0.0
0.0
estimate
0.00
20
202
90
818
1.14
0.46
6.1
4.5
—
—
—
0
0
112
1033
1.13
0.46
5.6
4.2
0.0
0.0
estimate
0.00
24
197
22
274
0.79
0.46
6.5
8.3
—
—
—
0
0
156
1469
1.13
0.45
7.0
5.0
9930.9
3600.7
e6/l
0.48
14
39
31
369
0.82
0.43
2.6
2.8
0.8
0.8
mmol/l
0.42
31
337
99
1071
0.89
0.41
4.6
5.6
1.2
1.2
mmol/l
0.38
93
961
0
15
0.00
0.41
0.0
1.1
—
—
—
0
0
0
16
0.00
0.41
0.0
1.1
—
—
—
0
0
0
17
0.00
0.41
0.0
1.1
—
—
—
0
0
0
17
0.00
0.41
0.0
4.3
—
—
—
0
0
0
17
0.00
0.41
0.0
1.0
—
—
—
0
0
35
298
1.20
0.40
5.1
6.4
2.3
1.4
mmol/l
0.55
26
242
0
18
0.00
0.40
0.0
1.3
—
—
—
0
0
0
18
0.00
0.40
0.0
1.3
—
—
—
0
0
0
18
0.00
0.40
0.0
1.3
—
—
—
0
0
0
18
0.00
0.40
0.0
1.1
—
36.5
—
0
10
0
18
0.00
0.40
0.0
1.3
—
7.3
—
0
12
0
18
0.00
0.40
0.0
1.0
—
485.0
—
0
11
0
18
0.00
0.40
0.0
1.3
—
—
—
0
0
0
18
0.00
0.40
0.0
1.3
—
—
—
0
0
16
202
0.78
0.38
2.8
2.9
3.9
4.2
kpa
0.44
16
192
57
633
0.88
0.36
2.7
2.8
26.6
33.1
u/l
1.09
57
602
5
78
0.64
0.36
1.2
1.3
—
—
—
0
0
19
232
0.81
0.35
2.6
3.7
6.0
5.8
kpa
0.31
19
223
47
417
1.15
0.34
2.3
1.8
—
—
—
0
0
6
47
1.28
0.32
1.2
1.4
—
—
—
0
0
7
53
1.33
0.31
1.0
1.3
—
—
—
0
0
7
54
1.30
0.30
1.6
1.4
—
—
—
0
0
7
54
1.30
0.30
1.6
1.4
—
—
—
0
0
49
541
0.89
0.29
1.9
2.4
—
—
—
0
0
6
82
0.73
0.24
1.2
1.0
—
—
—
0
0
6
85
0.70
0.24
3.5
2.5
—
—
—
0
0
12
147
0.81
0.24
1.4
2.1
11.8
12.7
nmol/l
0.11
12
130
7
95
0.73
0.22
2.0
2.9
4.5
4.3
pmol/l
—
7
81
80
847
0.92
0.21
2.1
2.2
68.0
78.6
nmol/l
3.03
69
720
0
11
0.00
0.21
0.0
1.0
—
—
—
0
0
0
11
0.00
0.21
0.0
1.0
—
—
—
0
0
0
11
0.00
0.21
0.0
1.9
—
—
—
0
0
0
11
0.00
0.21
0.0
1.9
—
—
—
0
0
0
10
0.00
0.21
0.0
1.2
—
—
—
0
0
0
12
0.00
0.21
0.0
1.2
—
—
—
0
0
0
12
0.00
0.21
0.0
1.0
—
—
—
0
0
0
12
0.00
0.21
0.0
1.2
—
—
—
0
0
0
12
0.00
0.21
0.0
1.2
—
—
—
0
0
0
12
0.00
0.21
0.0
1.8
—
—
—
0
0
0
13
0.00
0.21
0.0
1.8
—
—
—
0
0
0
13
0.00
0.21
0.0
1.4
—
—
—
0
0
0
13
0.00
0.21
0.0
1.8
—
—
—
0
0
0
13
0.00
0.21
0.0
1.8
—
—
—
0
0
0
13
0.00
0.21
0.0
1.0
—
—
—
0
0
0
13
0.00
0.21
0.0
1.4
—
—
—
0
0
0
13
0.00
0.21
0.0
1.1
—
—
—
0
0
0
13
0.00
0.21
0.0
1.8
—
—
—
0
0
44
476
0.91
0.19
2.3
3.1
2.5
2.5
mmol/l
0.10
37
413
14
164
0.85
0.19
4.4
2.8
80.7
56.5
ml/min/173m2
—
6
65
5
67
0.74
0.17
1.2
1.2
—
—
—
0
0
5
67
0.74
0.17
1.2
1.2
—
—
—
0
0
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
6
80
0.75
0.15
1.8
2.0
1.0
0.4
u/ml
—
6
38
95
985
0.95
0.14
3.9
4.2
—
—
—
0
0
16
179
0.89
0.12
1.4
1.5
—
—
—
0
0
20
217
0.92
0.09
2.4
3.1
124.6
236.4
ng/l
1.76
15
190
7
65
1.08
0.08
2.1
1.5
—
—
—
0
0
6
74
0.81
0.07
1.0
1.3
—
—
—
0
0
8
78
1.03
0.07
1.6
1.6
—
—
—
0
0
9
104
0.86
0.06
1.1
2.6
—
—
—
0
0
16
149
1.08
0.05
1.4
1.4
—
—
—
0
0
56
572
0.97
0.03
1.7
1.8
1246.3
1177.3
nmol/l
0.19
47
415
97
980
0.99
0.02
2.5
2.1
79.9
92.9
pmol/l
3.29
72
500
14
147
0.95
0.01
1.1
1.4
—
—
—
0
0
46
466
0.98
0.00
3.3
3.8
68.1
219.8
ng/l
1.61
36
407
11
111
0.99
0.00
2.0
4.1
26.1
24.0
mmol/l
1.19
11
105
21
211
0.99
0.00
4.1
6.5
1.0
1.3
mmol/l
0.78
21
198
90
895
1.01
0.00
2.8
2.3
—
—
—
0
0
5
58
0.86
0.00
1.2
1.5
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.4
—
30.2
—
0
5
0
5
0.00
0.00
0.0
1.4
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
0.00
0.0
1.1
—
—
—
0
0
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
0
7
0.00
0.00
0.0
1.6
—
—
—
0
0
0
8
0.00
0.00
0.0
1.1
—
—
—
0
0
0
7
0.00
0.00
0.0
1.7
—
1246.6
—
0
7
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
0
7
0.00
0.00
0.0
1.1
—
—
—
0
0
0
6
0.00
0.00
0.0
1.5
—
—
—
0
0
0
7
0.00
0.00
0.0
1.1
—
—
—
0
0
0
7
0.00
0.00
0.0
2.0
—
1.2
—
0
7
0
6
0.00
0.00
0.0
2.5
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
10.0
—
0
6
0
8
0.00
0.00
0.0
1.3
—
—
—
0
0
0
8
0.00
0.00
0.0
1.1
—
—
—
0
0
0
7
0.00
0.00
0.0
1.1
—
—
—
0
0
0
6
0.00
0.00
0.0
1.3
—
—
—
0
0
0
6
0.00
0.00
0.0
1.3
—
—
—
0
0
0
9
0.00
0.00
0.0
1.2
—
—
—
0
0
0
7
0.00
0.00
0.0
1.6
—
—
—
0
0
0
8
0.00
0.00
0.0
2.6
—
75.8
—
0
8
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
5
57
0.88
0.00
1.2
1.5
—
—
—
0
0
0
7
0.00
0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.3
—
—
—
0
0
0
8
0.00
0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
0.00
0.0
1.0
—
—
—
0
0
Mortality – FinRegistry
↥This endpoint is excluded from FinRegistry analyses (omitted endpoint).
Relationships between endpoints
↥Index endpoint: PDMED_ENTACAPONE – Use of entacapone
GWS hits: -
This endpoint is excluded from FinRegistry analyses (omitted endpoint).